Gram Positive (Carreno) Flashcards

(48 cards)

1
Q

Penicillin Coverage

A

Strep pneumo
E. coli
PSSA
NO MOD/HIGH COVERAGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Penicillin Distribution

A

WIDELY DISTRIBUTED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

3rd Gen Cephalosporins (6)

aka “3rd Gen Ceph”

A
Cefdinir
Cefixime
Cefoperazone
Ceftaxime
Ceftazidime
Ceftriaxone

MOA: prevent transpeptidation reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

3rd Gen Ceph Coverage

A

G+: Strep pneumo, MSSA
G-: E.coli, Kleb pneumo

NO HIGH COVERAGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

3rd Gen Ceph Distribution (4)

A

CNS (good)
Intra-abdomen
Urine
Skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Type 1 beta-lactam allergy
+
Conditions

A

Immediate
IgE-mediated

Anahpylaxis within minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Type 2 beta-lactam allergy
+
Conditions

A

Production of cytotoxic Abs
IgG + IgM mediated

Thrombocytopenia, nephritis, dose/duration dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Type 3 beta-lactam allergy
+
Conditions

A

IMMUNE COMPLEX MEDIATED
Formation of immune complexes
IgG + IgM

Serum sickness within 7-14d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Type 4 beta-lactam allergy
+
Conditions

A
CELL MEDIATED (NO ABs)
T-cell dependent

Inflammation + contact dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Macrolides

A

Eryhtromycin
Clarithromycin
Azithromycin

MOA: bind 50S subunit, prevent peptide bond formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Macrolide Coverage

A
S.pneumo
\+
H.influenza
M. catarrhalis
Mycoplasma
Chlamydia
Leginoella
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Macrolide Distribution

A

Upper Resp
Lower Resp
Tissues (i.e. cervix, ovaries, prostate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Key Clinical Uses:

Erythromycin

A

Strep pneumo

Promotility agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Key Clinical Uses:

Clarithromycin

A

Community Acquired Pneumonia (CAP)
Mycobacterium Avium Intracellularae (MAI)
H.pylori

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Key Clinical Uses:

Azithromycin

A
URTI (upper respiratory infections)
CAP
MAI
Cystic Fibrosis
COPD exacerbations
Chlamydial infections
Gonorrhea (@ high doses)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Macrolide: ADEs

A

Diarrhea
Vomiting
QT-prolongation
CYP3A4 interactions (E > C > A) i.e. STATINS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Fluoroquinolones

A

MOA: Toposiomerase/gyrase inhibition

ATYPICAL BACTERIA
Moxifloxacin (G+)
Levofloxacin (broad/both)
Ciprofloxacin (G-)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Coverage: Moxifloxacin

A

G+
Strep pneumo
E.coli, Kleb pneumo, G- anaerobes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Coverage: Levofloxacin

A

BROAD (both)
Strep pneumo
Ecoli, Kleb pneumo, PSAR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Coverage: Ciprofloxacin

A

G-
NO G+ activity
E.coli, Kleb pneumo, PSAR

21
Q

Fluoroquinolone Absorption/Bioavailability

A

Moxi + Levo –> 100%

Cipro –> 80%

22
Q

Fluoroquinolone Distribution

A

Lungs: Moxi + Levo
Urine: Levo + Cipro
Intra-abdomen: Moxi, Levo, Cipro

23
Q

Fluoroquinolone Excretion

A

Renal: Levo + Cipro
Hepatic: Moxi

24
Q

Major Fluoroquinolone ADE

A
QT Prolongation
Tendinitis + Tendon Rupture
Hypersensitivity
N/V
Diarrhea
Dizziness
Headaches
Insomnia
25
ABCs of Staph aureus
``` A --> absence of resistance elements B --> beta-lactamase presence C --> changes in PBP D --> d-ALA-d-ALA alterations (VRSAs) E --> extra-thick walls ```
26
Penicillinase-Resistant Penicillins (2) + Dosing
``` Oxacillin Nafcillin 2g IV q4h (SAME FOR BOTH) NO ADJUSTMENT FOR RENAL -monitor liver enzymes + interstitial nephritis ```
27
Penicillinase-Resistant Penicillins: Coverage
NO G- ACTIVITY | Strep pneumo, MSSA
28
Penicillinase-Resistant Penicillins: Distribution
Blood Skin Urine (?)
29
1st Gen Cephs (4)
Cefazolin (PO) Cephalexin (IV) Cephadroxil (PO) Cephalothin (IV)
30
1st Gen Cephs: Coverage
Strep pneumo, MSSA | E.coli
31
1st Gen Ceph: Distribution
Skin Urine (POOR CNS)
32
Beta-lactam + beta-lactamase inhibitor (3)
Amoxacillin/Clavulanate Ampicillin/Sulbactam Pipercillin/Tazobactam
33
Coverage: Amox/Clav + Amp/Sulbactam
Strep pneumo, MSSA E.coli **sulbactam selectively toxic vs. acinetobacter
34
Coverage: Piper/Tazo
Strep pneumo, MSSA E.coli, Kleb pneumo, PSAR **additional G- anaerobe coverage
35
Coverage: Vancomycin
Strep pneumo, MSSA, MRSA, E.faecalis **NO G- IV --> MRSA and PO --> C.diff
36
Distribution: Vancomycin
Low PO Bioavailability Blood Urine Lung, bone, CNS, heart (?)
37
Distribution: Daptomycin
Skin Heart (Inactivated in lungs)
38
Coverage: Daptomycin
Strep pneumo, MSSA/MRSA, E.faecalis | **NO G-
39
Daptomycin ADEs
Skeletal muscle toxicity Concurrent use of statin Eosinophili pneumonia (rare)
40
Telavancin: Type + ADEs
Lipogylcopeptide QTc prolongation + red-man syndrome 2x potential nephrotoxicity as vancomycin
41
Linezolid: Coverage
Strep pneumo, MSSA/MRSA, E.faecalis | **NO G-
42
Linezolid: Distribution
Low serum concentrations EXCELLENT for lungs Skin Urine
43
Linezolid: Info and ADEs
100% Bioavailability No renal dose adjustment Serotonin response syndrome Peripheral/otic neuropathy Thrombocytopenia/anemia
44
Tigecycline: Coverage
Strep pneumo, MSSA/MRSA, E.faecalis E.coli, Kleb pneumo + H.influenza, M.catarrahlis, Acinetobacter
45
Tigecycline: Distribution
Intra-abdomen Skin Lungs (?) VERY LOW SERUM/URINE concentrations **adjust for hepatic dysfunction
46
Tigecycline: ADEs
N/V
47
Ceftaroline: Coverage
Strep pneumo, MSSA/MRSA | E.coli, Kleb pnemo
48
Ceftaroline: Distribution
Lungs Skin Other (?) **adjust for CrCl < 50mL/min